AI Science Tracker

The First Affiliated Hospital of Wenzhou Medical University

1 discovery from 2024

Discoveries

Machine-learning screening identified three compounds with measured ULK1 inhibition

A Gaussian naive-Bayes classifier using ECFP6 fingerprints ranked commercial compounds from a 13-million-compound library, followed by docking, property filtering and manual selection. Researchers purchased and assayed 25 candidates; three showed micromolar ULK1 inhibition, with reported IC50 values of 37.11 ± 4.41, 7.67 ± 2.82 and 3.15 ± 0.77 μM. The molecules were purchased rather than newly synthesized, and this entry does not claim absolute chemical novelty. The study’s comparator MRT68921 was more potent; the results do not establish cellular activity or clinical utility.

Technology: Gaussian naive-Bayes classifier on ECFP6 molecular fingerprints (NB-ECFP6)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The paper reports 25 purchased candidates tested in a biochemical ULK1 kinase assay; three had measured micromolar inhibition with IC50 values 37.11 ± 4.41, 7.67 ± 2.82 and 3.15 ± 0.77 μM.
  • Still unknown: The candidates were purchased, not synthesized. The reported assays do not establish cell activity or clinical effect; the reference MRT68921 was more potent in the paper’s comparison. Absolute structure novelty is not claimed here.
  • AI role: The NB-ECFP6 model screened a large commercial compound set and prioritized candidates for downstream docking and biochemical testing.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11485869/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC11485869/pdf/IFMC_16_2385288.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary PMC full article and linked publisher-version PDF, including methods, kinase assay results, date and author affiliation block..

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.